Finoriq research workspace
Atea Pharmaceuticals, Inc. (AVIR) SEC Filings & Filing Highlights
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops. Review AVIR SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
- Company
- Atea Pharmaceuticals, Inc. (AVIR)
- Ticker
- AVIR
- Market Cap
- $385.3M
- Latest Price
- $4.815
- Industry
- Biotech & Pharma
Atea Pharmaceuticals, Inc. (AVIR) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Atea Pharmaceuticals, Inc. (AVIR).
| Event | Form | Date |
|---|---|---|
| Atea Pharmaceuticals, Inc.: Shareholder voteOn June 18, 2026, Atea Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Holders o... | 8-K5.07 | 2026-06-22 |
| Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business UpdateAtea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update | 8-K2.02 | 2026-05-12 |
| Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results andAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and | 8-K2.02 | 2026-03-05 |
| Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Heal...Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference | 8-K2.02 | 2026-01-08 |
| Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business UpdateAtea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | 8-K2.02 | 2025-11-12 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.